Japan's Transgenic And National Medical Center Collaborate On New Flu Diagnosis
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based International Medical Center of Japan and biotech firm Transgenic will jointly research and develop new antibodies for flu virus diagnosis. The center will use gene-engineered mice provided by Transgenic to develop an H1N1 antibody. The antibody will help to quickly diagnose the flu in patients. The two aim to commercialize the technology inside medical facilities this winter. (Click here for more - Japanese language
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.